This study could not achieve full blinding due to the nature of the interventionreduced glutathione requires intravenous administration, while the control group only received oral entecavir therapy
Clinically tested: improves pigmentation by 50.68% and reduces redness by 26.51%
To view or add a comment, sign in FDA Approves Oral Semaglutide by Novo Nordisk for CV Risk Reduction in Adults with Type 2 Diabetes
Retatrutide is currently in phase 3 clinical trials, which are expected to conclude in 2026
By combining three receptor targets into a single molecule, researchers aim to achieve enhanced reduction of weight, improved blood glucose control, and potentially greater metabolic flexibility compared to earlier therapies
Many healthcare providers are more familiar with injectable GLP-1 therapies, given their longer history